Core Viewpoint - 微脉公司 has submitted its listing application to the Hong Kong Stock Exchange, with招商证券国际 and 德意志银行 acting as joint sponsors [1] Company Overview - 微脉 is a pioneer and leader in AI-enabled full-cycle management services in China, aiming to connect hospitals, doctors, and patients to reconstruct the healthcare service value chain [3] - The company is one of the top three full-cycle management service providers in China by revenue in 2024 and the largest patient-oriented AI-enabled full-cycle management service provider [3] - 微脉's services cover the entire health management process from pre-treatment to post-treatment, leveraging its position as one of the few official managed health management partners of public healthcare institutions in China [3] Technology and Innovation - The company has developed CareAI, one of the first AI medical management platforms in China, utilizing a multi-agent system (M.A.S.) and mixed model (MoM) architecture [4] - 微脉 operates the only provincial AI medical research institution in China, continuously advancing AI and health management through real-world data to enhance patient management efficiency and accuracy [4] Market Potential - The full-cycle management market in China has grown from RMB 16.3 billion in 2020 to RMB 61.4 billion in 2024, with a compound annual growth rate (CAGR) of 39.3% [4] - The market is projected to reach RMB 365.4 billion by 2030, indicating a CAGR of 34.6% from 2024 to 2030, highlighting significant growth potential [4] Financial Performance - 微脉 reported revenues of approximately RMB 512 million, RMB 628 million, and RMB 653 million for the fiscal years 2022, 2023, and 2024, respectively [5] - The company incurred losses of approximately RMB 414 million, RMB 150 million, and RMB 193 million for the same fiscal years [5] - The gross profit margins for the respective years were 17.2%, 18.9%, and 19.9%, indicating a gradual improvement in profitability [6]
新股消息 | 微脉递表港交所 为中国前三大全病程管理服务提供商之一
智通财经网·2025-06-27 01:23